Please be advised that Associates of Cape Cod, Inc. (ACC) has updated its Privacy Policy. By visiting our website or using services provided by ACC, you are accepting the processes and procedures described in the Privacy Policy.

ACC also uses cookies on our websites. Cookies allow us to give you the best browsing experience and help us to better understand how you use our site. You can disable cookies within your settings, but this may affect certain functionally on our website. Please read our updated Cookies Policy for information about the cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking "I Accept", you confirm that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of information by ACC in accordance with said policies.

About Beacon Diagnostics® Laboratory

Beacon is a fully CLIA-certified (license no. 22D1021258) reference laboratory specializing in (1→3)-β-D-glucan analysis services to support the diagnosis of Invasive Fungal Disease (IFD). Serving clinical and reference laboratories, we offer a rapid, cost-effective alternative to in-house testing.

The laboratory is directed by Patricia Devine, M.D., and along with the expert staff at Beacon Diagnostics® Laboratory, we provide clients with rapid diagnostic and analytical services, to assist in the medical evaluation of patients suspected of having invasive fungal infections.

We currently hold certifications and licenses in Massachusetts, California, Maryland, Pennsylvania and Rhode Island. Copies can be viewed by clicking here.

You can also find information concerning the applications and latest findings of (1→3)-β-D-glucan testing in patients on the website, as well as links to other websites of interest to the mycotic disease community.

Patients at High Risk For IFD

Immunosuppressed patients are at high risk for developing invasive fungal disease, which is often difficult to diagnose.

Affected patient populations include:
  • Cancer patients undergoing chemotherapy
  • Stem Cell and Organ Transplant patients
  • Burn patients
  • HIV patients
  • ICU patients
Our laboratory also tests veterinary samples.